KAS
SRNE

Kestra Advisory Services’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Kestra Advisory Services’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-18,272
Closed -$16.2K – 2348
2022
Q4 		$16.2K Sell
18,272
-40
-0.2% -$53 ﹤0.01% 2225
2022
Q3 		$29K Sell
18,312
-585
-3% -$1.33K ﹤0.01% 2058
2022
Q2 		$38K Sell
18,897
-6,507
-26% -$11.3K ﹤0.01% 2061
2022
Q1 		$59K Buy
25,404
+6,075
+31% +$18.9K ﹤0.01% 1959
2021
Q4 		$90K Sell
19,329
-2,661
-12% -$16.5K ﹤0.01% 1948
2021
Q3 		$168K Buy
21,990
+7,863
+56% +$66.7K ﹤0.01% 2001
2021
Q2 		$137K Buy
14,127
+300
+2% +$2.39K ﹤0.01% 1925
2021
Q1 		$114K Sell
13,827
-4,258
-24% -$45K ﹤0.01% 1799
2020
Q4 		$131K Buy
+18,085
New +$145K ﹤0.01% 1765

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Kestra Advisory Services's SRNE Position: Q1 2023 in Review

Kestra Advisory Services sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 18,272 shares — an estimated $16.2K sold.

Kestra Advisory Services first reported a position in SRNE in Q4 2020 and held it in 9 quarters. The position peaked at $168K in Q3 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Kestra Advisory Services reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Kestra Advisory Services sold 18,272 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $16.2K.
  • Kestra Advisory Services first reported a position in Sorrento Therapeutics, Inc. in Q4 2020 and held it in 9 quarters.
  • Kestra Advisory Services's Sorrento Therapeutics, Inc. position peaked at $168K in Q3 2021.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Kestra Advisory Services's 13F filing for Q1 2023, filed 12 May 2023.